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IMPORTANCE Symptoms of stiff-person syndrome (SPS), stiff-limb syndrome (SLS), or
progressive encephalomyelitis with rigidity, myoclonus, or other symptoms (SPS-plus) can
occur with several autoantibodies, but the relative frequency of each antibody, syndrome
specificity, and prognostic implications are unclear.
OBJECTIVE To report the clinical and immunologic findings of a large cohort of patients with
stiff-person spectrum disorder (SPSD), including SPS, SLS, and SPS-plus.
DESIGN, SETTING, AND PATIENTS This study retrospectively examined a case series (January 1,
1998, through December 31, 2014) of immunologic investigations performed in a
neuroimmunology referral center. The study included 121 patients with clinical features of
SPSD. Data analysis was performed from July 1, 2015, through November 1, 2015.
MAIN OUTCOMES ANDMEASURES Analysis of clinical-immunologic associations, including
autoantibodies to 8 proteins expressed in inhibitory synapses.
RESULTS Themedian age of the patients was 51 years (interquartile range, 40-61 years), and
75 (62.0%) were female. Fifty (41.3%) had SPS, 37 (30.6%) had SPS-plus, 24 (19.8%) had SLS,
and 10 (8.3%) had SPS or SLS overlapping with ataxia, epilepsy, or encephalitis. Fifty-two
patients (43.0%) had glutamic acid decarboxylase (GAD65) antibodies (2 with
γ-aminobutyric acid–A [GABA-A] receptor antibodies), 24 (19.8%) had α1-subunit of the
glycine receptor (GlyR) antibodies (2 with GAD65 antibodies), 5 (4.1%) had other antibodies,
and 40 (33.1%) tested negative for antibodies. None had gephyrin or glycine transporter
antibodies. Among themain immunologic groups (GAD65 antibodies, GlyR antibodies, and
antibody negative), those with GAD65 antibodies were more likely to be female (45 [86.5%]
of 52, 8 [36.4%] of 22, and 18 [45.0%] of 40, respectively; P < .001), have systemic
autoimmunity (34 [65.4%] of 52, 7 [31.8%] of 22, and 13 [32.5%] of 40, respectively;
P = .004), and have longer delays in being tested for antibodies (median, 3 vs 0.5 and 1 year;
P < .001). Patients with GAD65 antibodies were more likely to develop SPS (27 [51.9%] of 52)
or overlapping syndromes (8 [15.4%] of 52) than patients with GlyR antibodies (5 [22.7%]
and 0 [0%] of 22, respectively), whomore often developed SPS-plus (12 [54.5%] of 22 vs 7
[13.5%] in those with GAD65 antibodies); antibody-negative patients had an intermediate
syndrome distribution. In multivariable analysis, symptom severity (P = .001) and
immunologic group (P = .01) were independently associated with outcome. Compared with
patients with GlyR antibodies, those with GAD65 antibodies (odds ratio, 11.1, 95% CI, 2.3-53.7;
P = .003) had worse outcome. Patients without antibodies had similar outcome than patients
with GlyR antibodies (odds ratio, 4.2, 95% CI, 0.9-20.0; P = .07).
CONCLUSIONS AND RELEVANCE In SPSD, symptom severity and presence and type of
antibodies are predictors of outcome.
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S tiff-person syndrome (SPS) is a disorder characterizedby fluctuating muscle rigidity and painful spasms thatoccur spontaneously or are triggered by diverse
stimuli.1,2 Partial or segmental forms of the disorder, such as
stiff-limb syndrome (SLS) and themore severe disease called
progressive encephalomyelitis with rigidity and myoclonus
(PERM), areusually consideredwithin the spectrumof SPS,3-6
but there is an increasing recognition of atypical and overlap-
ping syndromes. For all these disorders, which we collec-
tively termed stiff-personspectrumdisorder (SPSD), there isevi-
denceofunderlying immunemechanisms that target proteins
mainly expressed by the inhibitory synapses. Six autoanti-
gens have been identified, including glutamic acid decarbox-
ylase (GAD65),7,8 the α1-subunit of the glycine receptor
(GlyR),9,10 amphiphysin,11 gephyrin,12 dipeptidyl peptidase–
like protein 6 (DPPX),13,14 and the γ-aminobutyric acid–A
(GABA-A) receptor (GABAaR).15 Some of these immune re-
sponseshavebeensuggestedtobeassociatedwithdistinctvari-
ants of SPSD,16 but thedegree of syndrome specificity and im-
plications for treatment and prognosis are unclear. Because
some autoantigenswere recently discovered and SPS is a rare
disease,most studieshave focusedona limitednumberof au-
toantibodies (GAD65orGlyR)andwell-definedsyndromes (SPS
or PERM) without examining the entire spectrum of clinical-
immunologic associations and the implications of being anti-
body negative. To address these issues, we investigated the
clinical featuresof 121patientswithSPSD,determinedthepres-
ence of autoantibodies to 8 potential targets of the inhibitory
synapse, and compared the syndromes among the most fre-
quent immunophenotypes. In addition,weprovide the treat-
ment,outcome,andprognostic factorsof 75patients forwhom
long-term follow-up information was available.
Methods
Study Design and Participants
We retrospectively reviewed the clinical information of pa-
tients with SPSD seen by us (57 cases) or whose serum or ce-
rebrospinal fluid (CSF) samples were referred to our labora-
tory for antibody testing from January 1, 1998, through
December 31, 2014. Data analysis was performed from July 1,
2015, through November 1, 2015. Stiff-person spectrum dis-
order was clinically defined by the presence of symptoms of
axial stiffness andmuscle spasms not restricted to the classic
presentationofSPSbutalso including formswithpartial ordis-
tal limbdistributionor symptomsof encephalomyelitis. Clini-
cal information was obtained by us or the referring physi-
cians with a structured questionnaire.
One hundred forty-six patients were initially identified as
having possible SPSD. Of these, 20 were excluded after other
disorders were identified (eMaterial in Supplement) and
another 5 because of suboptimal information. Overall, 121
patients had the final diagnosis of SPSD, comprising 4
groups: (1) classic SPS: rigidity in axial trunk, sometimes
involving proximal limbs, in association with muscle spasms,
resulting in abnormal axial posture1; (2) SLS: affecting 1 or
more limbs with distal rigidity and abnormal posturing of
hands or feet5; (3) SPS-plus, including patients with all or par-
tial elements of PERM: brainstem dysfunction, myoclonus,
upper or lower motor neuron symptoms, sensory deficits,
sphincter or autonomic dysfunction, seizures, and cognitive
changes6; and (4) overlapping syndromes, including patients
with SPS or SLS in association with cerebellar ataxia, epi-
lepsy, or limbic encephalitis.17-20
Treatments were classified as (1) symptomatic (eg,
GABAergic drugs), (2) first-line immunotherapies (intrave-
nous corticosteroids, intravenous immunoglobulin, or
plasma exchange alone or combined), (3) second-line immu-
notherapies (rituximab, cyclophosphamide), and (4) long-
term oral immunotherapy (prednisone, azathioprine, myco-
phenolate mofetil, cyclosporine).
Thedelay todiagnosiswas calculatedas thedifferencebe-
tween thepatient’s age at the timeof autoantibody testing and
the age at symptom onset. Neurologic disability was mea-
suredusing themodifiedRankin Scale (mRS).21 Thedegree of
improvement was calculated as the difference between the
maximummRS score during the disease and the score at the
last follow-up. Improvement of at least 1 point with an mRS
score of0 to 2 at the last follow-upwas considered a goodout-
come; a score of 3 or higher or no change in themRS scorewas
consideredabadoutcome.Written informedconsent for stud-
ieswasobtained frompatientsor their families. The studywas
approvedby the institutional reviewboards of theHospital of
the University of Pennsylvania and Hospital Clinic, Univer-
sity of Barcelona.
Antibody Assays
Paired serum and CSF samples were available from 65 pa-
tients, only serum from 50, and only CSF from 6. Antibody
studies were performed using previously reported tech-
niques, which are described in the eMaterial in the Supple-
ment. SerumorCSF samples of 245patientswereusedas con-
trols, including samples from 30 healthy individuals, 20
patients with neurodegenerative diseases, and 195 patients
with immune-mediated central nervous system disorders
(eMaterial in Supplement).
Statistical Analysis
Demographic information and symptoms were analyzed
using the Fisher exact test, Fisher-Freeman-Halton test (an
extension for rxc contingency tables), or Mann-Whitney test,
Key Points
Question Do autoantibodies have prognostic implications in
stiff-person spectrum disorder (SPSD)?
Findings In this retrospective case series that included 121
patients, those with glutamic acid decarboxylase antibodies had
worse outcome than patients with glycine receptor antibodies or
patients who tested negative for antibodies. In contrast, the type
of syndrome did not predict outcome.
Meaning In SPSD, the presence and type of autoantibodies are
predictors of outcome.
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as appropriate. Because of a skewed distribution, log trans-
formation was used for duration of follow-up. The maximum
mRS score was dichotomized as low (range, 0-3) or high
(range, 4-6). Factors that influenced outcome were assessed
by univariable binary logistic regression. Factors associated
with a bad outcome (P < .10) were included in a multivariable
binary logistic regression model and approached by back-
ward stepwise procedure; only the variables that remained
significant were considered as independent predictors. Odds
ratios (95% CIs) were used to measure the effect of predic-
tors. SPSS statistical software, version 19 (SPSS Inc), was used
for the analyses.
Results
General Clinical Features
Seventy-five (62.0%) of 121 patients were women. The me-
dian age at symptom onset was 51 years (interquartile range
[IQR], 40-61 years), and the median delay to diagnosis was 2
years (IQR,0-4years).Fiftypatients (41.3%)hadSPS,37 (30.6%)
hadSPS-plus, 24 (19.8%)hadSLS, and 10 (8.3%)hadSPSorSLS
overlappingwith cerebellar ataxia (6 cases), epilepsy (3 cases),
or limbicencephalitis (1 case).Clinical features,diagnostic tests,
and outcome according to immunologic groups are listed in
Table 1 and according to the type of syndrome in eTable 1 in
the Supplement.
Neurophysiologic studies were performed in 84 patients,
revealing continuous motor unit activity in 52 (61.9%), with a
similar proportion of positive cases across all syndromes
(eTable 1 in the Supplement). Only 7 patients (5.8%) had
abnormal magnetic resonance imaging findings, including
high T2 signal in temporal lobes in 2 patients with overlapping
syndromes (1 limbic encephalitis and 1 epilepsy) and focal or
diffuse high T2 signal in 5 patients with SPS-plus (2 brain, 2
brainstem, and 1 spinal cord abnormalities). Three patients
(2.5%) had cancer (2 breast, 1 colon), 1 each presenting with
SLS, SPS-plus, and overlapping syndromes.
Patients with SPS-plus had higher mRS scores (more dis-
abled) than those with SPS and SLS (median, 4; IQR, 3-5; me-
dian,4; IQR,2.5-4[P = .001];andmedian,3; IQR,2-4[P = .002],
respectively) (eTable 1 in the Supplement). In addition to first-
line immunotherapy, patients with SPS-plusweremore likely
to receive long-termoral immunotherapythanthosewithother
syndromes, and patients with overlapping neurologic syn-
dromes were more likely to receive second-line immuno-
therapy (eTable 1 in the Supplement). Symptomatic GABAer-
gicdrugsweremore frequentlyused in typical SPS (42 [84.0%]
vs 16 [66.6%] in SLS, 21 [56.7%] in SPS-plus, and 5 [50.0%] in
overlapping syndromes, P = .006).
Antibody Findings
Eighty-onepatients (66.9%)hadautoantibodiesagainst inhibi-
torysynapticproteins, including52(43.0%)withGAD65(2with
concurrent GABAaR antibodies), 24 (19.8%)with GlyR (2with
concurrent GAD65 antibodies), 5 (4.1%)with other antibodies
(2GABAaR, 2 amphiphysin, 1DPPX), and40 (33.1%)whowere
antibody negative. Paired serum and CSF samples were stud-
ied in 26 (50.0%) of 52 patientswithGAD65 antibodies and 14
(58.3%) of 24 patients with GlyR antibodies; in 3 (11.5%) of 26
patients, GAD65 antibodies were detected only in CSF, and in
6 (42.8%) of 14 patients, GlyR antibodies were detected only
in serum. None of the patients had antibodies against gephy-
rin, glycine transporter (GlyT) 1orGlyT2.Threepatients (2.4%)
of 121, without antibodies against any of the 8 target antigens,
had serum antibodies against unknown neuronal cell surface
antigens determined in live neuronal cultures.
Fifteen (6.1%) of 245 controls had GlyR antibodies in se-
rum: 4 had cerebellar ataxia, 2 had epilepsy, 4 had anti–N-
methyl-D-aspartate receptor encephalitis, and 5 hadmultiple
sclerosis. Five controls (2.0%) had GABAaR antibodies: 1 had
cerebellar ataxia, 3 had epilepsy, and 1 had anti–N-methyl-D-
aspartate receptorencephalitis. PairedCSFsampleswereavail-
able from 12 of these 20 patients, and all tested negative for
GlyR andGABAaR antibodies. The titers of GlyR antibodies in
serum tended to be lower in the controls than inpatientswith
SPSD (median titer, 1/80; range, 1/40 to 1/640; vs median ti-
ter, 1/160; range, 1/40 to 1/1280; P = .06). The titers of GAB-
AaR antibodies in serum of controls and patients with SPSD
were similar (median titer, 1/40; range, 1/20 to 1/160; vs me-
dian titer, 1/40; range, 1/20 to 1/40; P = .09). None of the con-
trols with GlyR antibodies had symptoms of SPSD; 4 of 5 con-
trolswith serumGABAaRantibodies hadprominent seizures.
Clinical Comparisons of Immunologic Groups
These studies focused on the main immunologic groups
(GAD65 antibodies, GlyR antibodies, and antibody negative),
whichcomprised114 (94.2%)of 121patients; the2patientswith
coexisting GAD65 and GlyR antibodies were excluded. Pa-
tients with GAD65 antibodies or antibody-negative patients
were more likely to develop SPS than those with GlyR anti-
bodies,whomore frequentlydevelopedSPS-plus (P = .002; see
list of symptoms in Table 1). Patients with GAD65 antibodies
were investigated for antibodies later than thosewithGlyRan-
tibodies or antibody-negative patients (median delay to diag-
nosis, 3years; IQR, 1-6years;0.5year; IQR,0-2years [P < .001];
and1year; IQR,0-5years [P = .02], respectively) andhad lower
maximum mRS scores (lower symptom severity) compared
with thoseof theother2groups (medianmRSscore forGAD65,
3.5; IQR, 2-4; GlyR, 4; IQR, 3.5-5 [P = .01]; and antibody nega-
tive, 4; IQR, 3-5 [P = .05], respectively). Patients with GAD65
antibodies were more likely to be female (45 [86.5%] of 52, 8
[36.4%]of 22, and 18 [45.0%]of40, respectively;P < .001) and
had more frequent systemic autoimmune or endocrine dis-
orders (34 [65.4%] of 52, 7 [31.8%] of 22, and 13 [32.5%] of 40,
respectively;P = .004).On theother hand, patientswithGlyR
antibodies had more frequent CSF pleocytosis than those of
the other 2 groups (7 [38.9%] of 18 vs 2 [10.0%] of 20 for the
GAD65 group and 4 [14.8%] of 27 for the antibody-negative
group, P < .001). None of the antibody-negative patients had
CSF oligoclonal bands (11 [47.8%] of 23, 5 [29.4%] of 17, and 0
of 19 in the GAD65 antibodies, GlyR antibodies, or antibody-
negative groups, respectively;P < .001). No significant differ-
ences were identified in terms of age at onset of symptoms,
electrophysiologic findings, immunotherapies used, and re-
lapses among the 3 immunological groups (Table 1).
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Because SPSD without antibodies has been infrequently
reported in the literature,16 we further assessed the clinical
features of the 3 immunologic groups to compare only those
patients with SPSD and electromyographic findings of
agonist-antagonist continuous motor unit activity. This
subgroup analysis revealed that the antibody-negative
patients still composed one-third of the cases, and the main
distinctive clinical features among immunologic groups
Table 1. Clinical Features of theMain Immunologic Groupsa
Clinical Feature
GAD65 Antibodies
(n = 52 [43.0%])
GlyR Antibodies
(n = 22 [18.2%])b
Antibody Negative
(n = 40 [33.1%]) P Value
Female sex 45 (86.5) 8 (36.4) 18 (45.0) <.001
Age at onset, median (IQR), y 52.5 (39.0-62.0) 46.0 (39.0-60.0) 50.0 (39.0-59.0) .74
Delay to diagnosis, median (IQR), y 3.0 (1.0-6.0) 0.5 (0-2.0) 1.0 (0-5.0) <.001c
Syndrome
SPS 27 (51.9) 5 (22.7) 17 (42.5)
.002
SLS 10 (19.2) 5 (22.7) 7 (17.5)
SPS-plus 7 (13.5) 12 (54.5) 15 (37.5)
Overlapping syndromes 8 (15.4) 0 1 (2.5)
Hyperekplexia 14 (26.9) 11 (50.0) 11 (27.5) .009
Myoclonus 6 (11.5) 9 (40.9) 9 (22.5) .07
Brainstem 3 (5.8) 10 (45.5) 7 (17.5) .002
Pyramidal 7 (13.5) 11 (50.0) 11 (27.5) .004
Sphincter 1 (1.9) 7 (31.8) 5 (12.5) .008
Sensory 0 5 (22.7) 3 (7.5) .01
Autonomic 5 (9.6) 7 (31.8) 6 (15.0) .06
Insomnia 2 (3.8) 6 (27.3) 7 (17.5) .045
Systemic autoimmune disordersd 34 (65.4) 7 (31.8) 13 (32.5) .004
CMUA on EMG 26/36 (72.2) 6/14 (42.9) 16/30 (53.3) .25
CSF pleocytosis 2/20 (10.0) 7/18 (38.9) 4/27 (14.8) <.001
CSF OCBs 11/23 (47.8) 5/17 (29.4) 0/19 (0) <.001
MaximummRS score, median (IQR) 3.5 (2-4) 4 (3.5-5) 4 (3-5) .02c
Symptomatic treatment 46 (88.5) 10 (45.5) 24 (60.0) <.001
Type of immunotherapy
Nontreated 9/45 (20.0) 2/18 (11.1) 6/28 (21.4)
.17
First line only 22/45 (48.9) 4/18 (22.2) 11/28 (29.3)
First line and long-term oral 4/45 (8.9) 7/18 (38.9) 4/28 (14.3)
First and second line 7/45 (15.5) 5/18 (27.8) 6/28 (21.4)
Othere 3/45 (6.7) 0 1/28 (3.6)
Cases with follow-up 41 (78.8) 14 (63.6) 24 (60.0) .13
Follow-up period, median (IQR), mo 34.0 (12.0-66.0) 11.0 (8.0-40.0) 12.0 (9.0-54.0) .049c
Relapsing course 13/41 (31.7) 6/14 (42.9) 6/24 (25.0) .77
Final mRS score, median (IQR) 3 (1-3) 1 (1-3) 2.5 (1-4) .14
Improvement
Treated 24/32 (75.0) 11/14 (78.6) 11/19 (57.9)
.14
Nontreated 3/9 (33.3) 0 4/5 (80.0)
Change in mRS score, median (IQR) 1 (0-1) 3 (0.75-4) 1 (0-2) .009c
Abbreviations: CMUA, continuous motor unit activity; CSF, cerebrospinal fluid;
EMG, electromyography; GAD65, glutamic acid decarboxylase; GlyR, α1-subunit
of the glycine receptor; IQR, interquartile range; mRS, modified Rankin scale;
OCBs, oligoclonal bands; SLS, stiff-limb syndrome; SPS, stiff-person syndrome;
SPS-plus, progressive encephalomyelitis with rigidity, myoclonus, or other
symptoms.
a Data are presented as number (percentage) of patients unless otherwise
indicated.
b Excludes 2 patients with concurrent GAD65 and GlyR antibodies.
c Mann-Whitney test: delay to diagnosis for patients with GAD65 antibodies vs
GlyR antibodies, P < .001; GAD65 antibodies vs antibody negative, P = .02;
and GlyR antibodies vs antibody negative, P = .052; maximummRS score for
patients with GAD65 antibodies vs GlyR antibodies, P = .01; GAD65 antibodies
vs antibody negative, P = .05; and GlyR antibodies vs antibody negative,
P = .44; follow-up period for patients with GAD65 antibodies vs GlyR
antibodies, P = .04; GAD65 antibodies vs antibody negative, P = .053; and
GlyR antibodies vs antibody negative, P = .70; and change in mRS score for
GAD65 antibodies vs GlyR antibodies, P = .002; GAD65 antibodies vs
antibody negative, P = .41; and GlyR antibodies vs antibody negative, P = .04.
d Fifty-four patients (44.6%), including 18 with type 1 diabetes mellitus, 13 with
thyroiditis, 2 with celiac disease, 2 with psoriasis, 2 with vitiligo, 2 with
Raynaud syndrome, and 15 with thyroid, antinuclear antibody,
double-stranded DNA, or gastric parietal cell antibodies.
e Includes 3 patients who received long-term oral immunotherapy (not
preceded by first-line therapy) and 1 patient who received chemotherapy for
colon cancer.
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were similar to those indicated above (eTable 2 in the
Supplement).
Among the group of 10 patients with SPS or SLS, and
overlapping syndromes, 8 had GAD65 antibodies (5 cerebel-
lar ataxia and 3 epilepsy), 1 had limbic encephalitis and
amphiphysin antibodies, and 1 had cerebellar ataxia and
was antibody negative. Five patients without GAD65 and
GlyR antibodies had autoantibodies against other known
antigens (2 amphiphysin, 2 GABAaR, and 1 DPPX; eMaterial
in Supplement).
Clinical Outcome
Clinical outcome was available for 75 patients (62.0%), with a
median follow-up of 18 months (IQR, 11-60 months). Patients
with GlyR antibodies had a greater degree of improvement
than those with GAD65 antibodies or without antibodies (me-
dian change inmRS score for patients with GlyR antibodies, 3;
IQR, 0.75-4; for patient with GAD65 antibodies, 1; IQR, 0-1
[P = .002]; and antibody-negative patients, 1; IQR, 0-2
[P = .04]) (Table 1). The eFigure in the Supplement shows
patients’ outcome according to the clinical syndrome and
immunologic group. At the last follow-up, 40 patients (53.3%)
had a bad outcome, and 35 (46.7%) had a good outcome. Nine
patients (12.0%) died, 5 as a result of systemic complications
(pneumonia, pulmonary embolism, sepsis, intestinal perfora-
tion, status epilepticus) and 4 of cardiorespiratory arrest; 6
patients had GAD65 antibodies, 2 were antibody negative, and
1 had GlyR antibodies. In univariable analysis, the factors sig-
nificantly associated with a bad outcome were symptom
severity and presence of GAD65 antibodies (Table 2). Inmulti-
variable analysis, symptom severity and immunologic group
were independently associated with outcome (Table 2). Com-
pared with patients with GlyR antibodies, those with GAD65
antibodies (odds ratio, 11.1, 95% CI, 2.3-53.7; P = .003) had
worse outcome. Patients without antibodies had similar out-
come than patients with GlyR antibodies (odds ratio, 4.2, 95%
CI, 0.9-20.0; P = .07).
Discussion
This study reveals that in a cohort of 121 patients with SPSD
only 50 (41.3%) had typical SPS, and the overall prognosis de-
pendedmore on the underlying immunemechanism and se-
verity of symptoms than on the type of syndrome. Among 8
potential autoantigens, GAD65 andGlyRwere by far themost
frequently identified, leading to3 immunologicgroups:GAD65
antibodies (43.0%), GlyR antibodies (19.8%), and antibody
negative (33.1%).
The clinical features associated with GAD65 antibodies
were similar in many respects to those previously repor-
ted.20,22-24 When compared with patients with GlyR antibod-
ies or without antibodies, those with GAD65 antibodies were
more likely to be female and have systemic autoimmune or
endocrine disorders. The main neurologic differences among
the 3 immunophenotypes depended on the relative fre-
quency of symptoms included within the spectrum of PERM
(hyperekplexia, myoclonus, brainstem, pyramidal, sensory,
or autonomic dysfunction), which were mainly associated
with GlyR antibodies, whereas the development of classic
SPS or SLS with or without overlapping syndromes (eg, cer-
ebellar ataxia, epilepsy) more frequently occurred with
GAD65 antibodies. Patients without antibodies had a distri-
bution of symptoms between those associated with GlyR and
GAD65 antibodies. Although these differences were statisti-
cally significant, there was no clear syndrome-immunologic
specificity, indicating that any form of SPSD can potentially
occur with any of the 3 main immunologic groups considered
here.
A frequent concern that arises in clinical practice is how
frequently other antibodies that are less accessible in clinical
laboratories (eg, DPPX, GABAaR, gephyrin) are missed
because they are not tested for. The current data indicate that
in our setting (a reference center for autoimmune and para-
neoplastic disorders of the central nervous system) the fre-
quency of antibodies other than GAD65 and GlyR is low.
Indeed, only 5 patients (4.1%) had antibodies to amphiphy-
sin, DPPX, or GABAaR, and none had antibodies to gephyrin,
GlyT1, or GlyT2. These transporters were included because
their mutations result in symptoms similar to those reported
Table 2. Variables Related to a BadOutcome (mRS Scores of 3-6
or No Improvement)
Variable Odds Ratio (95% CI) P Value
Univariable Analysis
Sex 1.56 (0.59-4.1) .37
Age at onset 1.02 (0.99-1.05) .18
Clinical syndrome .85
SPS (n = 32) … …
SLS (n = 14) 0.58 (0.16-2.1) .40
SPS-plus (n = 25) 0.72 (0.25-2.1) .54
Overlapping syndromes (n = 4) … (0-) .99
Delay to diagnosisa 1.20 (0.96-1.48) .11
MaximummRS group (4-6 vs 0-3) 3.9 (1.50-10.4) .005
Follow-up period (loge) 0.89 (0.57-1.41) .63
Immunotherapy
Nontreated … …
Treated 1.18 (0.37-3.8) .78
Immunologic group .08
GlyR antibodies (n = 14) … …
Antibody negative (n = 22) 2.5 (0.60-10.4) .21
GAD65 antibodies (n = 39) 4.5 (1.20-16.9) .03
Multivariable Analysis
MaximummRS group 7.5 (2.3-24.5) .001
Immunologic group .01
GlyR antibodies … …
Antibody negative 4.2 (0.90-20.0) .07
GAD65 antibodies 11.1 (2.3-53.7) .003
Abbreviations: ellipses, data not applicable; GAD65, glutamic acid
decarboxylase; GlyR, α1-subunit of the glycine receptor; loge, natural logarithm;
mRS, modified Rankin scale; SLS, stiff-limb syndrome; SPS, stiff-person
syndrome; SPS-plus, progressive encephalomyelitis with rigidity, myoclonus, or
other symptom.
a For patients tested for autoantibodies after 5 years of symptom onset (n = 15),
the delay to diagnosis was considered 6 years.
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in mutations or autoimmunity to GlyR (hyperekplexia).25
Compared with previous studies,24,26 our findings reveal a
larger group of seronegative patients (40 [33.1%] of 121
patients vs 16 [23.5%] of 68 patients24 and 18 [18.2%] of 99
patients26). This finding is likely explained by the fact that 20
patients (16.5%) were referred to our center for assessment of
novel or atypical antibodies after clinical or commercial anti-
body tests (mostly composed of GAD65, amphiphysin, or
GlyR) tested negative. This referral pattern emphasizes even
more the low frequency of DPPX and GABAaR antibodies
among patients who test negative for the more common
autoantibodies. The low frequency of amphiphysin antibod-
ies has been reported in previous series.27,28 Nevertheless,
amphiphysin antibodies are important to consider in the
paraneoplastic context, mainly breast and lung cancer.27
Detection of GABAaR antibodies in CSF or at high titers in
serum (≥1/160) is associated with encephalitis with severe
seizures or status epilepticus but without SPSD.15 Therefore,
detection of these antibodies only in serum and at low titers
should be interpreted with caution. Similar caution should be
considered for low serum titers of GlyR antibodies, which as
reported here and in previous studies29-31 occurred in 6% to
10% of controls without SPSD (eg, multiple sclerosis, cerebel-
lar degeneration, or epilepsy). When CSF was available, none
of these patients had GlyR antibodies in CSF, a finding that
needs confirmation with a larger number of patients. In con-
trast, for GAD65 antibodies, we used 2 previously validated
techniques (immunohistochemistry with rat brain and cell-
based assay) that only reveal these antibodies if they are
present at moderate to high titers, similar to those associated
with neurologic disorders; titers equivalent to radioimmuno-
assay values of 2000 U/mL or less (seen in many patients
with diabetes mellitus) are not detected with the techniques
used here.20,31
Anovel findingof our study is that theunderlyingmecha-
nism (eg, presence and type of antibodies) but not the type of
syndrome (eg, SPS, SLS, SPS-plus, or overlapping syndrome)
was an independent predictor of outcome. For example, al-
thoughat diseasediagnosis patientswithGlyRantibodieshad
more severe neurologic deficits thanpatientswithGAD65 an-
tibodies (and similar to antibody-negative patients), the out-
comeofpatientswithGlyRwasbetter thanthatofpatientswith
GAD65antibodies. This finding couldbeexplainedbyanearly
diagnosis in patients with GlyR antibodies (as shown in our
study),which is likely owing to amore rapid and severe symp-
tomonset (eg, SPS-plus or PERM) and the presence of CSF in-
flammatorychangeswhencomparedwithpatientsof theother
groups.Moreover, patientswithGlyRantibodieswere treated
more aggressively (eg, first-line immunotherapy combined
withsecond-lineor long-termoral immunotherapy) thanthose
of the other 2 groups, who more often received first-line im-
munotherapyandsymptomatic treatment.On theotherhand,
disorders associated with antibodies to cell surface antigens,
such asGlyR, are usuallymore responsive to immunotherapy
than those associated with intracellular antigens, such as
GAD65 or paraneoplastic antigens.
Our study has limitations related to its retrospective na-
ture and possible selection of cases toward complex syn-
dromes (with elements of PERM or overlapping syndromes).
These limitationsmay explain the lower frequency of GAD65
antibody–positive cases comparedwith that of other series (52
[43.0%] of 121 patients vs 50 [73.5%] of 68 patients24 and 79
[79.8%] of 99 patients26). Despite this, to our knowledge, the
current series provides the most comprehensive autoanti-
body screening reported todate in SPSD.One could argue that
using cultures of hippocampal neuronswemissed antibodies
directed to novel antigens restricted to the brainstem or spi-
nal cord, a possibility to consider in future studies.
Conclusions
Several practical implications can be derived from this and
previous studies.32-34 First, SPSD is a complex group of disor-
ders, with multiple autoantigens but 3 predominant immuno-
phenotypes (GAD65 antibodies, GlyR antibodies, and anti-
body negative). Second, this immunologic characterization
and the severity of symptoms are predictors of outcome.
Third, although PERM predominantly occurs with GlyR anti-
bodies, it can potentially be associated with other autoanti-
bodies. This implication is important because, contrary to the
concept that PERM carries a poor prognosis,35 our findings
indicate that this depends on the underlying immune
response (worse in patients with GAD65 antibodies than
antibody-negative patients and patients with GlyR antibod-
ies). Fourth, DPPX and GABAaR are infrequent in SPSD; our
data do not support upfront testing for these antibodies
unless the clinical context (eg, gastrointestinal symptoms,
hyperekplexia, encephalopathy for DPPX,36 or prominent sei-
zures for GABAaR) suggest their investigation.
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